10x Genomics, Inc. Announces 2026 Annual Meeting Voting Results
Key Highlights from the Annual Meeting
- Date of Meeting: June 4, 2026 (via live webcast)
- Quorum Achieved: Holders of 117,542,161 shares of Class A and Class B common stock were present, representing approximately 90.5% of the total eligible votes.
- Proposals Voted: Three proposals were submitted to vote, all receiving clear outcomes.
Detailed Voting Results
Proposal 1: Election of Directors
Shareholders approved the election of three Class I directors to serve three-year terms, expiring at the 2029 annual meeting, or until their successors are elected and qualified:
| Nominee | Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Serge Saxonov | 164,137,381 | 15,559,860 | 557,329 | 18,560,948 |
| Benjamin J. Hindson | 162,942,766 | 16,761,532 | 550,270 | 18,560,950 |
| John R. Stuelpnagel | 155,628,365 | 24,072,179 | 554,023 | 18,560,951 |
Implication: The strong support for all director nominees confirms shareholder confidence in the current leadership team, which could be viewed positively by the market. However, the votes against John R. Stuelpnagel were somewhat higher than for the other two nominees, which may be worth monitoring for any governance signals.
Proposal 2: Ratification of Independent Registered Public Accounting Firm
Shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:
- Votes For: 197,719,939
- Votes Against: 458,231
- Abstentions: 637,346
- Broker Non-Votes: 0
Implication: The overwhelming support for Ernst & Young as auditors provides reassurance about the integrity of financial oversight and should be viewed as a positive for both governance and transparency.
Proposal 3: Non-Binding, Advisory Vote to Approve Executive Compensation
Shareholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers:
- Votes For: 176,677,540
- Votes Against: 2,828,730
- Abstentions: 748,296
- Broker Non-Votes: 18,560,952
Implication: The strong approval supports management’s pay structure and could be considered a green light for existing compensation practices. This helps reduce the risk of shareholder activism on pay issues in the immediate future.
Additional Information
- Principal executive offices: 6230 Stoneridge Mall Road, Pleasanton, CA 94588
- Trading Symbol: TXG (The Nasdaq Stock Market LLC)
- Fiscal Year End: December 31
Potentially Price-Sensitive Insights
- All directors nominated by the Board were re-elected with significant majorities, signaling stability in leadership and potentially positive sentiment from institutional investors.
- The ratification of Ernst & Young as auditors with virtually no opposition underpins confidence in the company’s financial reporting, which is a key consideration for institutional investors and could attract more interest.
- Approval of executive compensation suggests minimal shareholder dissent regarding management practices, reducing the likelihood of near-term governance issues or proxy battles.
No new material business initiatives, financial restatements, or other events were disclosed during the meeting that would immediately and directly impact the share price beyond the normal course of governance-related updates.
Conclusion
The results of the 2026 Annual Meeting indicate strong shareholder support for 10x Genomics’ leadership, governance, and compensation practices. While the votes against one director were higher than for others, all proposals passed by wide margins. These outcomes denote organizational stability and continued investor confidence, both of which are generally positive indicators for the company’s share value.
Disclaimer: This article is based on the official SEC 8-K filing for 10x Genomics’ 2026 Annual Meeting and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own research and consult financial professionals before making investment decisions.
